Analysts See $-0.52 EPS for XOMA (XOMA); Shorts at DATALOGIC SPA BOLOGNA ORDINARY SHARES PO (DLGCF) Raised By 1037.84%

April 17, 2018 - By Marguerite Chambers

DATALOGIC SPA (OTCMKTS:DLGCF) Logo

DATALOGIC SPA BOLOGNA ORDINARY SHARES PO (OTCMKTS:DLGCF) had an increase of 1037.84% in short interest. DLGCF’s SI was 126,300 shares in April as released by FINRA. Its up 1037.84% from 11,100 shares previously. With 100 avg volume, 1263 days are for DATALOGIC SPA BOLOGNA ORDINARY SHARES PO (OTCMKTS:DLGCF)’s short sellers to cover DLGCF’s short positions. It closed at $41 lastly. It is down 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts expect XOMA Corporation (NASDAQ:XOMA) to report $-0.52 EPS on May, 8.They anticipate $1.78 EPS change or 77.39% from last quarter’s $-2.3 EPS. After having $-0.16 EPS previously, XOMA Corporation’s analysts see 225.00% EPS growth. The stock increased 2.63% or $0.58 during the last trading session, reaching $22.66. About 30,310 shares traded. XOMA Corporation (NASDAQ:XOMA) has risen 184.45% since April 17, 2017 and is uptrending. It has outperformed by 172.90% the S&P500.

XOMA Corporation discovers, develops, and commercializes antibody therapeutics in the United States, Europe, and the Asia Pacific. The company has market cap of $188.81 million. The company's product candidates include X358, a human negative allosteric modulating insulin receptor antibody that is in Phase II proof-of-concept study for the treatment of patients with hypoglycemia due to congenital hyperinsulinism and hypoglycemia in post-bariatric surgery patients; X213, a allosteric inhibitor for the treatment of prolactinoma and anti-psychotic-induced hyperprolactinemia; and X129, a potent fragment of a monoclonal antibody for the treatment of patients with acute severe hypoglycemia. It has a 31.13 P/E ratio. The Company’s preclinical product candidates comprise interleukin 2 for the treatment of metastatic melanoma and renal cell carcinoma; and anti-parathyroid receptor, a G-protein-coupled receptor for the treatment of hyperparathyroidism and humoral hypercalcemia of malignancy.

Among 7 analysts covering Xoma Limited (NASDAQ:XOMA), 2 have Buy rating, 0 Sell and 5 Hold. Therefore 29% are positive. Xoma Limited had 23 analyst reports since July 23, 2015 according to SRatingsIntel. H.C. Wainwright maintained it with “Buy” rating and $49.0 target in Thursday, January 18 report. The rating was downgraded by Wedbush to “Neutral” on Monday, November 14. The firm has “Neutral” rating given on Wednesday, July 22 by Ladenburg Thalmann. H.C. Wainwright reinitiated it with “Buy” rating and $38 target in Tuesday, October 17 report. As per Tuesday, December 19, the company rating was maintained by Wedbush. On Tuesday, November 7 the stock rating was maintained by H.C. Wainwright with “Buy”. The firm has “Outperform” rating by Wedbush given on Tuesday, September 5. H.C. Wainwright maintained it with “Buy” rating and $1500 target in Thursday, August 10 report. The firm has “Neutral” rating given on Wednesday, July 22 by Piper Jaffray. The firm earned “Buy” rating on Tuesday, November 14 by H.C. Wainwright.

Datalogic S.p.A. manufactures and sells automatic data capture and industrial automation products for retail, manufacturing, transportation and logistics, and healthcare industries worldwide. The company has market cap of $. The firm operates in Automatic Data Capture, Industrial Automation, Informatics, and Corporate divisions. It has a 32.36 P/E ratio. It offers in-counter/on-counter scanners/scales, including single plane scanners, and bi-optic and multi-plane imaging scanner/scales; self-shopping devices; loss prevention solutions; presentation scanners; general duty and industrial handheld scanners; mobile computers such as pocket-sized to full-alpha-keyboard hand-held devices, industrial PDAs, pistol-grip terminals, vehicle mounted computers, and middleware software solutions; and laser marking solutions for the manufacture of automotive, electronics, medical devices, and high precision metals.

XOMA Corporation (NASDAQ:XOMA) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>